Revolution Medicines Q3 EPS $(0.99) Beats $(1.01) Estimate
Portfolio Pulse from bharat@benzinga.com
Revolution Medicines reported Q3 losses of $(0.99) per share, beating the analyst consensus estimate of $(1.01) by 1.98 percent. However, this is a 37.5 percent increase in losses compared to the same period last year.
November 06, 2023 | 9:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Revolution Medicines reported better than expected Q3 losses, but the losses increased significantly compared to last year.
While the company beat the consensus estimate, the increase in losses compared to the same period last year could be a concern for investors. This mixed result may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100